Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma
Aim. To assess the outcomes of patients with unresectable intrahepatic cholangiocellular carcinoma (ICC) treated by a tailored therapeutic approach, combining systemic with advanced image-guided local or locoregional therapies. Materials and Methods. Treatment followed an algorithm established by a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2016/8732521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554250150871040 |
|---|---|
| author | Ricarda Seidensticker Max Seidensticker Kathleen Doegen Konrad Mohnike Kerstin Schütte Patrick Stübs Erika Kettner Maciej Pech Holger Amthauer Jens Ricke |
| author_facet | Ricarda Seidensticker Max Seidensticker Kathleen Doegen Konrad Mohnike Kerstin Schütte Patrick Stübs Erika Kettner Maciej Pech Holger Amthauer Jens Ricke |
| author_sort | Ricarda Seidensticker |
| collection | DOAJ |
| description | Aim. To assess the outcomes of patients with unresectable intrahepatic cholangiocellular carcinoma (ICC) treated by a tailored therapeutic approach, combining systemic with advanced image-guided local or locoregional therapies. Materials and Methods. Treatment followed an algorithm established by a multidisciplinary GI-tumor team. Treatment options comprised ablation (RFA, CT-guided brachytherapy) or locoregional techniques (TACE, radioembolization, i.a. chemotherapy). Results. Median survival was 33.1 months from time of diagnosis and 16.0 months from first therapy. UICC stage analysis showed a median survival of 15.9 months for stage I, 9 months for IIIa, 18.4 months for IIIc, and 13 months for IV. Only the number of lesions, baseline serum CEA and serum CA19-9, and objective response (RECIST) were independently associated with survival. Extrahepatic metastases had no influence. Conclusion. Patients with unresectable ICC may benefit from hepatic tumor control provided by local or locoregional therapies. Future prospective study formats should focus on supplementing systemic therapy by classes of interventions (“toolbox”) rather than specific techniques, that is, local ablation leading to complete tumor destruction (such as RFA) or locoregional treatment leading to partial remission (such as radioembolization). This trial is registered with German Clinical Trials Registry (Deutsche Register Klinischer Studien), DRKS-ID: DRKS00006237. |
| format | Article |
| id | doaj-art-d13cd24833144d8a8c9fa0d1a477208d |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-d13cd24833144d8a8c9fa0d1a477208d2025-02-03T05:52:06ZengWileyGastroenterology Research and Practice1687-61211687-630X2016-01-01201610.1155/2016/87325218732521Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic CholangiocarcinomaRicarda Seidensticker0Max Seidensticker1Kathleen Doegen2Konrad Mohnike3Kerstin Schütte4Patrick Stübs5Erika Kettner6Maciej Pech7Holger Amthauer8Jens Ricke9Klinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyKlinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyKlinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyKlinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyZentrum für Gastrointestinale Tumoren (ZeGIT), Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyZentrum für Gastrointestinale Tumoren (ZeGIT), Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyKlinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyKlinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyKlinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyKlinik für Radiologie und Nuklearmedizin, Universitätsklinikum Magdeburg, Leipziger Strasse 44, 39120 Magdeburg, GermanyAim. To assess the outcomes of patients with unresectable intrahepatic cholangiocellular carcinoma (ICC) treated by a tailored therapeutic approach, combining systemic with advanced image-guided local or locoregional therapies. Materials and Methods. Treatment followed an algorithm established by a multidisciplinary GI-tumor team. Treatment options comprised ablation (RFA, CT-guided brachytherapy) or locoregional techniques (TACE, radioembolization, i.a. chemotherapy). Results. Median survival was 33.1 months from time of diagnosis and 16.0 months from first therapy. UICC stage analysis showed a median survival of 15.9 months for stage I, 9 months for IIIa, 18.4 months for IIIc, and 13 months for IV. Only the number of lesions, baseline serum CEA and serum CA19-9, and objective response (RECIST) were independently associated with survival. Extrahepatic metastases had no influence. Conclusion. Patients with unresectable ICC may benefit from hepatic tumor control provided by local or locoregional therapies. Future prospective study formats should focus on supplementing systemic therapy by classes of interventions (“toolbox”) rather than specific techniques, that is, local ablation leading to complete tumor destruction (such as RFA) or locoregional treatment leading to partial remission (such as radioembolization). This trial is registered with German Clinical Trials Registry (Deutsche Register Klinischer Studien), DRKS-ID: DRKS00006237.http://dx.doi.org/10.1155/2016/8732521 |
| spellingShingle | Ricarda Seidensticker Max Seidensticker Kathleen Doegen Konrad Mohnike Kerstin Schütte Patrick Stübs Erika Kettner Maciej Pech Holger Amthauer Jens Ricke Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma Gastroenterology Research and Practice |
| title | Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma |
| title_full | Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma |
| title_fullStr | Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma |
| title_full_unstemmed | Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma |
| title_short | Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma |
| title_sort | extensive use of interventional therapies improves survival in unresectable or recurrent intrahepatic cholangiocarcinoma |
| url | http://dx.doi.org/10.1155/2016/8732521 |
| work_keys_str_mv | AT ricardaseidensticker extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT maxseidensticker extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT kathleendoegen extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT konradmohnike extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT kerstinschutte extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT patrickstubs extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT erikakettner extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT maciejpech extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT holgeramthauer extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma AT jensricke extensiveuseofinterventionaltherapiesimprovessurvivalinunresectableorrecurrentintrahepaticcholangiocarcinoma |